Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)
Status:
Not yet recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety
and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability
syndrome which is the main cause of death in dengue fever.
Phase:
Early Phase 1
Details
Lead Sponsor:
George Washington University
Collaborators:
Allied Research Society Hospital Infantil de Niño Jesús de Barranquilla (HINJ) Naval Medical Research Center Universidad Bosque